Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Dazukibart | PF-06823859 | Phase 3 Clinical | Pfizer Inc | Polymyositis; Dermatomyositis; Myositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Muscular Diseases | Details |
Peginterferon beta-1a (CinnaGen) | Phase 3 Clinical | Cinnagen | Multiple Sclerosis, Relapsing-Remitting | Details | |
VSV-IFNbeta-NIS | Phase 2 Clinical | Vyriad | Lymphoma, T-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Mycosis Fungoides; Angioimmunoblastic T-cell Lymphoma; Carcinoma, Neuroendocrine; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral; Colorectal Neoplasms; Sarcoma; Multiple Myeloma; Myelodysplastic Syndromes; Histiocytoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell; Solid tumours | Details | |
VSV-hIFNbeta-NIS (University of Tennessee) | Phase 1 Clinical | The University Of Tennessee | Multiple Myeloma; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Lymphoma, T-Cell | Details | |
MEM-288 | MEM-288 | Phase 1 Clinical | Memgen | Head and Neck Neoplasms; Solid tumours; Carcinoma, Merkel Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
SCD-153 | SCD-153 | Phase 1 Clinical | Sun Pharma Advanced Research Company Ltd, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University | Alopecia Areata | Details |
This web search service is supported by Google Inc.